Tech Company Financing Transactions
Radar Therapeutics Funding Round
NFX, Biovision Ventures and Eli Lilly and Company invested in a $13.4 million Seed venture round for Radar Therapeutics. The financing round was recorded on 5/23/2024.
Transaction Overview
Company Name
Announced On
5/23/2024
Transaction Type
Venture Equity
Amount
$13,400,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds for the advancement of its internal programs, team expansion and partnering.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Berkeley, CA Undisclosed
USA
Berkeley, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Radar Therapeutics is pioneering a new treatment modality: precision-expressed mRNA-based therapeutics. Founded by pioneers in synthetic biology from leading institutions, Radar Therapeutics leverages the explosion in single-cell transcriptomic data, advances in our understanding of RNA-editing enzymes, and simple, elegant logic gates to make "smart" mRNAs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sophia Lugo
Chief Scientific Officer
Eerik Kaseniit
Browse more venture capital transactions:
Prev: 5/23/2024: Averlon venture capital transaction
Next: 5/23/2024: Alphaledger venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs